Technical Analysis for ARCT - Arcturus Therapeutics Ltd.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 20 DMA | Bearish | 0.00% | |
Fell Below 50 DMA | Bearish | 0.00% | |
MACD Bearish Signal Line Cross | Bearish | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
50 DMA Support | Bullish | -6.36% | |
Bollinger Band Squeeze | Range Contraction | -6.36% | |
BB Squeeze Started | Range Contraction | -6.36% | |
Inside Day | Range Contraction | -6.36% | |
Crossed Above 20 DMA | Bullish | -9.70% | |
Crossed Above 50 DMA | Bullish | -9.70% |
Alert | Time |
---|---|
Fell Below Lower Bollinger Band | about 15 hours ago |
Down 5% | about 18 hours ago |
Down 3% | about 18 hours ago |
Down 2 % | about 18 hours ago |
Fell Below 10 DMA | about 18 hours ago |
Get a Trading Assistant
- Earnings date: 03/05/2025
Arcturus Therapeutics Ltd. Description
Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine. MDX consists of a single bi-layer oral tablet, which includes both a rapid onset release metadoxine formulation and a slow release metadoxine formulation together providing the desired dual release profile. The new extended-release formulation prolongs the human plasma levels of metadoxine for up to 12 hours, which results in enhanced efficacy benefits. ADAIR is an oral, semi-solid, liquid-filled, hard gelatin capsule of an abuse-deterrent IR formulation of dextroamphetamine sulfate, which is manufactured as 10 mg capsules.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Drugs Health Sciences Pharmacology Euphoriants Amphetamine Cognitive Disorders Adhd Glutamate Tablet
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 45.0 |
52 Week Low | 14.3 |
Average Volume | 392,618 |
200-Day Moving Average | 22.16 |
50-Day Moving Average | 17.20 |
20-Day Moving Average | 16.87 |
10-Day Moving Average | 16.74 |
Average True Range | 1.37 |
RSI (14) | 45.36 |
ADX | 9.15 |
+DI | 22.78 |
-DI | 21.75 |
Chandelier Exit (Long, 3 ATRs) | 17.14 |
Chandelier Exit (Short, 3 ATRs) | 19.46 |
Upper Bollinger Bands | 18.01 |
Lower Bollinger Band | 15.74 |
Percent B (%b) | 0.2 |
BandWidth | 13.43 |
MACD Line | -0.17 |
MACD Signal Line | -0.17 |
MACD Histogram | -0.0002 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 18.46 | ||||
Resistance 3 (R3) | 18.63 | 18.06 | 18.08 | ||
Resistance 2 (R2) | 18.06 | 17.48 | 17.97 | 17.95 | |
Resistance 1 (R1) | 17.12 | 17.12 | 16.84 | 16.95 | 17.83 |
Pivot Point | 16.55 | 16.55 | 16.40 | 16.46 | 16.55 |
Support 1 (S1) | 15.61 | 15.97 | 15.33 | 15.44 | 14.55 |
Support 2 (S2) | 15.04 | 15.61 | 14.95 | 14.43 | |
Support 3 (S3) | 14.10 | 15.04 | 14.30 | ||
Support 4 (S4) | 13.93 |